External control groups can support regulatory decision-making in clinical trials, especially rare diseases. In Huntington’s disease (HD) there is a wealth of historical data, but matching historical data to clinical trials is challenging.
We use cookies to understand more about who's visiting our website, and, where we can, to provide you with a more tailored service. You can change your cookie settings at any time.